ArticleERJ open research2020

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.

David R Muccino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.